Johns Hopkins Diabetes GuideManagementType 1 Diabetes

Insulin Pump Management

Nestoras Mathioudakis, M.D., MHS, Saira Khan, M.D.
Insulin Pump Management is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

-- The first section of this topic is shown below --


  • Insulin pumps (technically called Continuous Subcutaneous Insulin Infusion, CSII) deliver insulin at programmed rates, from a pump worn externally through a small catheter tip inserted into the skin.
  • CSII is an option for treating type 1 diabetes or unstable, insulin-requiring type 2 diabetes.
  • Sensor-augmented insulin pump therapy: Insulin pump is used in conjunction with a continuous glucose monitor (CGM), which displays real-time blood glucose (BG) readings and allows patient to make informed decisions about insulin dosing.
  • Recently FDA approved pump (Medtronic MiniMed 670G system) offers insulin-only closed-loop system in which basal insulin doses are automatically adjusted up and down to prevent/respond to hypoglycemia and hyperglycemia.[25]
  • Automatic suspension of insulin delivery to prevent hypoglycemia is a useful safety feature for patients with hypoglycemic unawareness.
  • Only use rapid-acting (e.g. aspart, lispro or glulisine) or regular insulin (U-100). U-500 regular insulin has been studied in small case series and appears safe for use with CSII; however, the prescribing information from the manufacturer notes that its safety and efficacy for use in CSII has not been determined. While U-200 may be an attractive option for insulin-resistant patients who have high insulin requirements, U-200 insulin is currently available only in pen form and not intended for use in insulin pump.
  • A fully-automated closed-loop system ("artificial pancreas") based on CGM is not yet available commercially, but shows promise based on results from clinical trials.[4][1]

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: March 4, 2018